Merck has started a big study testing whether its immunotherapy drug, Keytruda, helps newly diagnosed lung cancer patients more if it is combined with Yervoy, a drug made by rival Bristol-Myers Squibb. But don't interpret the study as a bet the combination will prove effective.
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2017/10/06/merck-hedges-bets-with-keytruda-lung-study/
via IFTTT
No comments:
Post a Comment